RELEASE: Kenneth Kovan of BioVaxys to participate in MedInvest's Oncology Investor Conference (2)

(Information sent by the signatory company).

RELEASE: Kenneth Kovan of BioVaxys to participate in MedInvest's Oncology Investor Conference (2)

(Information sent by the signatory company)

-Kenneth Kovan, co-founder, president and chief operating officer of BioVaxys, will participate in the MedInvest Oncology Investor Conference

VANCOUVER, BC, Dec. 5, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that Kenneth Kovan, co-founder, president and COO, will participate in the MedInvest Oncology Investor Conference, to be held in New York on December 14-15, 2022.

In collaboration with the National Foundation for Cancer Research, the MedInvest Oncology Investor Conference is the leading conference for indication-specific investors. Attendees are active oncology investors and dedicated oncology companies seeking investment and partnership opportunities, including major life sciences and oncology venture capitalists, family offices, pharmaceutical executives, public and private oncology companies and foundations. The National Cancer Institute is the Presenting Partner for this year's Conference, with speakers including Greg Simon, who was most recently Chairman of the Biden Cancer "Moonshot" Initiative, leading immunologists and oncologists from Memorial Sloan Kettering and other institutions, and the I D world pharmaceutical.

Presentation details are as follows:

When: Wednesday, December 14, 2022 @ 4:10PM ESTWhere: Dorsey

"BioVaxys is honored to have been selected to speak at the MedInvest Oncology Investor Conference alongside a prestigious group of oncologists, investors and life sciences companies. We can't wait to share how we are leveraging our platform of haptenized proteins to create autologous immunotherapies against ovarian cancer and other malignancies," said James Passin, CEO and Co-Founder of BioVaxys.

Kovan has over 30 years of experience in biopharmaceuticals. Prior to founding BioVaxys Technology Corp., he was a corporate development partner at Horizon Discovery plc, a leader in gene editing, in the UK, and is a managing director and owner of Bingham Hill Ventures, a life sciences advisory firm he founded in 2012. He is a seasoned former biotech chief advisor and founder of biotech companies such as Avax Technologies, Inc. Kovan's professional experience includes technology transfer with Thomas Jefferson University, Strategic Marketing with SmithKline Beecham, and Global New Product Development with Wyeth-Ayerst. Kovan has extensive international business experience, having launched pharmaceutical brands in the Latin American and Asia/Pacific markets and led pharmaceutical development projects in Europe.

About BioVaxys Technology Corp.

Headquartered in Vancouver, BioVaxys Technology Corp. ( is a British Columbia-registered early-stage biotechnology company developing platforms for viral and oncology vaccines, as well as immunodiagnostics. The company is advancing the development of vaccines against SARS-CoV-2, SARS-CoV-1, and a sarbecovirus vaccine in general based on its haptenized viral protein technology, and is planning a clinical trial of its cellular vaccine. autologous haptenized drug used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for stage III and IV ovarian cancer. Also in development is CoviDTH®, a diagnostic to assess the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines and diagnostic technologies. BioVaxys common shares trade on the CSE under the stock symbol "BIOV" and are listed on the Frankfurt Bourse (FRA: 5LB) and in the United States (OTCQB: BVAXF).

Signed "James Passin"

James Passin, CEO 1 646 452 7054

Government and media relationsJB

Cautionary Note Regarding Forward-Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities law, including the United States Private Securities Litigation Reform Act of 1995. All statements except statements of historical fact, including herein, without limitation, statements relating to the Company's future operating or financial performance, are forward-looking statements. Forward-looking statements are often, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible" and similar expressions, or statements that the events, conditions or results "may", "may", "could" or "should" occur or be achieved. The forward-looking statements in this press release pertain to, among other things, the completion of the animal model study, regulatory approval for a Phase I study of its vaccine candidate BVX-1021 in humans, and the overall development of vaccines for BioVaxys, including any haptenized SARS-Cov-2 or SARS-CoV protein vaccine. There can be no guarantee that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied by such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections as of the date the statements are made and are based on a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, which, while are considered reasonable by the company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies, including, primarily but not limited to, the risk that BioVayxs vaccines will not be effective and/or will not receive approvals required regulations. With respect to BioVaxys' business, there are a number of risks that could affect the development of its biotech products, including, but not limited to, the need for additional capital to finance clinical trials, its lack of operating history, uncertainty as to whether its products will complete the lengthy, complex and costly clinical trial and regulatory approval process for new drug approvals required for marketing approval, uncertainty as to whether your autologous cell vaccine immunotherapy can be developed to produce safe and efficacious products and, if so, whether your vaccine products will be commercially accepted and profitable, the costs, delays and uncertainties and complications that are often encountered by development-stage biopharmaceutical companies, financial and development obligations under licensing agreements to protect your rights to its products and technologies, obtaining and protection of new intellectual property rights and the prevention of third party infringement and their reliance on third party manufacturing.

The company does not undertake any obligation to update forward-looking statements of beliefs, opinions, projections or other factors, should they change, except that


View original content: